Exploring the Attitudes, Barriers, Concerns, Differences, and Ethics (ABCDEs) of Healthcare Decision Making in Prospective Peripheral Indications for Vagus Nerve Stimulation Patients
探索迷走神经刺激患者预期外周适应症中医疗决策的态度、障碍、担忧、差异和道德 (ABCDE)
基本信息
- 批准号:10789644
- 负责人:
- 金额:$ 6.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-23 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAdultAffectAnatomyAttitudeAwardBrainCardiovascular systemCaregiversCatalogsCentral Nervous SystemCervicalChest wall structureClinicalComplementCranial NervesCraniotomyDataData SetDecision MakingDeep Brain StimulationDevelopmentDevicesDiseaseElectric StimulationElectroconvulsive TherapyElectrodesEligibility DeterminationEnrollmentEpilepsyEthical IssuesEthicsEvaluationFocus GroupsFundingGatekeepingHealth Care EthicsHealthcareHeart failureHumanImmuneImmune System DiseasesImmunologicsImplantIndividualInterviewIntractable EpilepsyKnowledgeMedicalMental DepressionMetabolicMetabolic DiseasesMethodsMotorNeurologicNeurologistNeurosurgeonNewly DiagnosedOperative Surgical ProceduresOrganParentsParticipantPatient RecruitmentsPatientsPerceptionPeripheralPharmaceutical PreparationsPhasePhysiciansPhysiologic pulsePopulationPopulation SizesProcessPsychiatristPublic HealthRecommendationResearchRiskSeriesSiteStandardizationStructureSurvey MethodologySystemTechnologyTranscranial magnetic stimulationUnited States Food and Drug AdministrationUnited States National Institutes of HealthVagus nerve structureWorkbarrier to carebehavioral healthcraniumdepressed patientdesignimplantable deviceimplantationinsightneuroregulationphysical conditioningprogramsprospectiverecruitresponsesocial stigmatreatment comparisontreatment responseuptakevagus nerve stimulation
项目摘要
The NIH Stimulating Peripheral Activity to Relieve Conditions (SPARC-V) initiative will primarily focus
on cervical vagus nerve stimulation (VNS). Despite VNS achieving its first Food and Drug Administration (FDA)
clearance in 2001 in drug resistant epilepsy and a second indication in difficult to treat depression in 2005,
VNS has made minimal public health impacts. Over 125,000 individuals are utilizing clinical VNS. This
relatively low uptake in proportion to the size of the population eligible for VNS suggests patients perceive VNS
poorly or have unaddressed ethical concerns regarding this technology. VNS is a unique form of invasive
neuromodulation requiring a VNS therapy pulse generator to be surgically implanted in the chest wall and a
tunneled electrode that delivers intermittent electrical stimulation to the vagus nerve. VNS differs from other
forms of electrical neuromodulation uniquely in its invasiveness. Compared to electroconvulsive therapy (ECT)
and deep brain stimulation (DBS) in that it indirectly affects the brain through a cranial nerve rather than
cortical stimulation so it does not require craniotomy like the latter. Additionally, adequate VNS therapy
response is delayed compared to other forms of electrical neuromodulation with ECT inducing response in the
order of 1 mo and DBS inducing motor response as early as the same day of device activation. The protracted
response trajectory generates ethical issues in neuromodulation particular to this technology deserving of
further consideration in order to understand VNS healthcare decision making.
REVEAL/SPARC-V offers a unique opportunity to observe a large population anticipating implantation
with VNS. The study will recruit adults seeking VNS therapy for both epilepsy and difficult to treat depression
and observe them after implantation to characterize VNS’s effects on peripheral systems such as the
cardiovascular, immunologic or metabolic systems in addition to their clinical response. These patients offer a
unique opportunity to characterize previously unexamined ethical issues and perceptions of VNS while the
technology is poised to be developed for additional peripheral indications.
We propose a mixed-methods evaluation to characterize VNS specific ethical factors that can impact
VNS acceptability for its current indications and to proactively assess these factors for emerging indications in
peripheral disease states. After a series of development focus groups a semi structured interview phase
assess VNS ethical considerations in depression, epilepsy and prospective peripheral indications in groups of
physicians, patients and their caregivers and perform thematic analysis. Additionally, we will use survey
methods to assess perceptions of stigma, acceptability, risks,benefits,invasiveness, and barriers to care
(defined as medical decision metrics). This work will crucially contribute to the under-examined ethics of VNS.
Our proposal will set the stage for better adoption of VNS for both central nervous system illnesses and
peripheral organ diseases.
NIH 刺激外周活动以缓解病情 (SPARC-V) 计划将主要关注
颈迷走神经刺激(VNS)。尽管 VNS 首次获得美国食品药品监督管理局 (FDA) 批准
2001年在耐药性癫痫方面获得批准,2005年在难以治疗的抑郁症方面获得第二个适应症,
VNS 对公共健康的影响微乎其微。超过 125,000 人正在使用临床 VNS。这
与符合 VNS 资格的人群规模相比,其接受率相对较低,这表明患者感知到了 VNS
对该技术的道德担忧尚未得到解决。 VNS 是一种独特的侵入性形式
神经调节需要通过手术将 VNS 治疗脉冲发生器植入胸壁和
隧道电极向迷走神经提供间歇性电刺激。 VNS 与其他的不同
电神经调节的形式以其独特的侵入性而闻名。与电休克治疗 (ECT) 相比
和深部脑刺激(DBS),因为它通过脑神经而不是间接影响大脑
皮质刺激,因此不需要像后者那样需要开颅手术。此外,充分的 VNS 治疗
与其他形式的电神经调节相比,ECT 诱导反应延迟
1 个月的顺序和 DBS 最早在设备激活的同一天就诱导运动反应。旷日持久的
反应轨迹在神经调节中产生伦理问题,特别是该技术值得
进一步考虑以了解 VNS 医疗保健决策。
REVEAL/SPARC-V 提供了观察大量预期植入的独特机会
与迷走神经刺激。该研究将招募寻求 VNS 治疗癫痫和难以治疗的抑郁症的成年人
并在植入后观察它们,以表征 VNS 对周围系统(例如
心血管、免疫或代谢系统以及临床反应。这些患者提供了
独特的机会来描述以前未经审查的道德问题和 VNS 的看法,同时
准备开发用于其他外周适应症的技术。
我们提出了一种混合方法评估来描述可能影响 VNS 的特定道德因素
VNS 对其当前适应症的可接受性,并主动评估这些因素以发现新兴适应症
周围疾病状态。经过一系列发展焦点小组之后,进入半结构化面试阶段
评估 VNS 在抑郁症、癫痫和预期外周适应症方面的伦理考虑
医生、患者及其护理人员并进行主题分析。此外,我们将使用调查
评估耻辱感、可接受性、风险、益处、侵入性和护理障碍的看法的方法
(定义为医疗决策指标)。这项工作将对 VNS 的道德审查做出至关重要的贡献。
我们的提案将为更好地采用 VNS 治疗中枢神经系统疾病和
周围器官疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lynn E Eberly其他文献
838-6 The impact of prior myocardial infarction, metabolic syndrome, and high white blood cell count on coronary heart disease mortality: The multiple risk factor intervention trial (MRFIT) 18-year follow-up experience
- DOI:
10.1016/s0735-1097(04)91755-x - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
Jerome D Cohen;Ronald J Prineas;Xin Zhi;Lynn E Eberly;Lewis H Kuller;James D Neaton; The MRFIT Research Group - 通讯作者:
The MRFIT Research Group
Lynn E Eberly的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lynn E Eberly', 18)}}的其他基金
REVEAL - Research Evaluating Vagal Excitation and Anatomical Linkages.
REVEAL - 评估迷走神经兴奋和解剖联系的研究。
- 批准号:
10709632 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
REVEAL - Research Evaluating Vagal Excitation and Anatomical Linkages.
REVEAL - 评估迷走神经兴奋和解剖联系的研究。
- 批准号:
10610556 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
Investigating the effects of VNS on central autonomic network and interoception
研究 VNS 对中枢自主网络和内感受的影响
- 批准号:
10893815 - 财政年份:2022
- 资助金额:
$ 6.08万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 6.08万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 6.08万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 6.08万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 6.08万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 6.08万 - 项目类别:
Standard Grant














{{item.name}}会员




